Calgon Carbon Launches Filtrasorb Rx for EPA PFAS Rules

The EPA's PFAS maximum contaminant level rules are landing on thousands of U.S. municipal water utilities. Compliance deadlines are closing in. The treatment options that work–granular activated carbon, ion exchange, reverse osmosis–each carry their own cost and logistics trade-offs.

Calgon Carbon, the world's largest activated carbon manufacturer and a wholly owned subsidiary of Kuraray (TYO: 3405), announced Tuesday a product built for that bottleneck. Filtrasorb Rx is a reactivated carbon designed to municipal drinking water specifications, backed by third-party validated performance data and the kind of technical support that lets engineers write it into procurement documents.

EPA PFAS Rules Drive Urgent Demand

The immediate catalyst is regulatory. The EPA's PFAS rules set strict limits for six perfluoroalkyl and polyfluoroalkyl substances in drinking water. Utilities that rely on activated carbon face a choice: buy virgin carbon repeatedly, incinerate spent media, or landfill it. All three are expensive. Virgin carbon prices have climbed. Disposal liability is real.

Reactivated carbon has long existed as a service buy–a utility ships spent carbon to a reactivation facility and gets back a product of unknown consistency. Quality varied. Specification writers had little to point to.

Filtrasorb Rx changes that. Calgon Carbon starts with its Filtrasorb virgin feedstock, runs it through a proprietary reactivation process, and returns a product with documented performance characteristics that the company says match or exceed virgin media. That lets utilities treat reactivated carbon as a specification-grade input, not a commodity gamble.

From Commodity to Specification-Grade